Evidence map›Paper›PMID 36407032›Full record

ArticleInternational journal of endocrinology and metabolism2022

Hypo- and Hyperphosphatemia at Admission as Independent Factors of Mortality of COVID-19 Patients: Findings from a Retrospective Cohort Study.

Marzieh Hadavi, Fakhredin Taghinezhad, Elham Shafiei, Sharif Hama Babakr, Saiyad Bastaminejad, Mohammadreza Kaffashian, Iraj Ahmadi, Aliashraf Mozafari

Open access · diamondAbstract read
In one paragraph

Article in International journal of endocrinology and metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Marzieh HadaviDepartment of Internal Medicine, School of Medicine, Shahid Mostafa Khomeini Hospital, Ilam University of Medical Sciences, Ilam, Iran.ORCID https://orcid.org/0000-0002-5851-8772
Fakhredin TaghinezhadClinical Research Development Unit, Shahid Mostafa Khomeini Hospital, Ilam University of Medical Sciences, Ilam, Iran.ORCID https://orcid.org/0000-0002-2566-5135
Elham ShafieiNon-communicable Diseases Research Center, Ilam University of Medical Sciences, Ilam, Iran.ORCID https://orcid.org/0000-0001-5689-5235
Sharif Hama BabakrIlam University of Medical Science, Ilam, Iran.ORCID https://orcid.org/0000-0002-4983-5899
Saiyad BastaminejadNon-communicable Diseases Research Center, Ilam University of Medical Sciences, Ilam, Iran.
Mohammadreza KaffashianDepartment of Physiology, School of Medicine, Ilam University of Medical Sciences, Ilam, Iran.
Iraj AhmadiNon-communicable Diseases Research Center, Ilam University of Medical Sciences, Ilam, Iran.
Aliashraf MozafariNon-communicable Diseases Research Center, Ilam University of Medical Sciences, Ilam, Iran.ORCID https://orcid.org/0000-0002-9962-3130
Medical University of Ilam · IRIlam University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Electrolyte imbalances are common in COVID-19 infection and are associated with poor outcomes in hospitalized patients. Objectives: This study examined whether serum phosphate imbalances at admission are associated with mortality in hospitalized COVID-19 patients. Methods: In this registry-based single-center retrospective cohort study, 1349 inpatients with COVID-19 were included from March 2020 to March 2021 in an academic hospital in Ilam (southwest Iran). The Cox proportional hazard (PH) regression model was applied to the data set of COVID-19. Results: The in-hospital median survival time for patients with low, normal, and high serum phosphate levels was 14, 25, and 8 days, respectively. In a multivariate model, adjusted for the other variables, patients with hypophosphatemia (adjusted hazard ratio [HR], 2.53; 95% CI, 1.15 - 5.58; P = 0.02) and hyperphosphatemia (adjusted HR, 1.77; 95% CI, 1.00 - 3.14; P = 0.05) had an increased mortality hazard compared with those who had normal levels of serum phosphate. Conclusions: Our results demonstrate associations of hypophosphatemia and hyperphosphatemia with increased in-hospital mortality in COVID-19 patients. Intensive medical care and more attention must be paid to COVID-19 patients with serum phosphate imbalances at admission.

Indexed as

COVID-19HyperphosphatemiaHypophosphatemiaIn-Hospital MortalitySARS-CoV-2

Identifiers

PMID36407032
PMCPMC9661755
OpenAlexW4285091624

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.